Go to: content | top | bottom | search
Division of Experimental Oncology
You are hereDivision of Experimental Oncology > Group Rüegg > Publications


2009 | 2008 | 2007 | 2006 | 2005


C. Rüegg and G.C. Alghisi (2009). Integrins in angiogenesis and angiogenesis inhibition. In Recent Results in cancer Research. Editors: Berdel, Kessel, Liersch, Springer Verlag

G-C. Alghisi, L. Ponsonnet, and C. Rüegg. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells PLoS ONE, 4(2): e4449

N. C. Brembilla, I. Cohen-Salmon, J.Weber, C. Rüegg, M. Quadroni, K. Harshman and M. A. Doucey (2009). Profiling of signaling proteins and T cell receptor signaling complex assembly in human CD4 T lymphocytes using RP protein arrays. Proteomics, 9:299-309

A. Murat, E. Migliavacca, I. Desbaillets, M-F Hamou, C. Rüegg, R. Stupp, M. Delorenzi, and M. E. Hegi Hypoxia Modulated Angiogenic and Inflammatory Response and Outcome in Glioblastoma. PLoS ONE, 4(6): e5947

C. Rüegg and S. Peters (2009). Thalidomide in small cell lung cancer : wrong drug or wrong disease ? J. Natl Cancer Inst, published on line, July 16, 2009. doi: 10.1093/jnci/djp208

M. Colzani, P. Waridel, J. Laurent, E. Faes, C. Rüegg, M. Quadroni (2009). Metabolic labeling and protein linearization technology allow the study of proteins secreted by cultured cells in serum-containing media. J Proteome Res, 2009 Aug 27. [Epub ahead of print]

C. Rüegg (2009). New answers to old questions in metastasis research. In Interdisziplinäres Zürcher Symposium, Edition 2009. Editor. C.A. Redaelli, In press

V. Baerenswyl, A. Zumsteg, N. Imaizumi, R. Schwendener, C. Rüegg and G. Christofori (2009). Myeloid cells contribute to tumor lymphangiogenesis. PLoS ONE, Sep 17;4(9):e7067.

E. Martina, M. Degen, C. Rüegg, A Merlo, M. M. Lino, R. Chiquet-Ehrismann, and F. Brellier (2009). Tenascin-W is overexpressed in glioma blood vessels and stimulates angiogenesis in vitro. FASEB J, in press





M. Degen, F. Brellier, S.Schenk, R. Chiquet-Ehrismann, R. Driscoll, K. Zaman, R. Stupp, C. Rüegg, W. Seelentag. Tenascin-W a novel biomarker in colon cancer (2008) Int. J. Cancer 122:2454-61 PubMed

C. Sessa, A. Guybal, GL Delconte and C. Rüegg. Biomarkers of angiogenesis in the development of antiangiogenic therapies in oncology : tools or decorations ? (2008) Nature Clin Pract Oncol 5:378-91 PubMed

L. Rossier-Pansier, F. Baruthio, C. Rüegg, A. Mariotti. Compartmentalization in membrane rafts defines a pool of N-cadherin associated with catenins and not engaged in cell-cell junctions in melanoma cells. (2008) J Cellular Biochem, 15:103:957-71; PubMed

Baruthio, F., Quadroni, M., Rüegg, C., and Mariotti, A Proteomics analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. (2008) Proteomics, 8:4733-47. PubMed

N. C. Brembilla, J. Weber, D. Rimoldi, S. Pradervand, G. Pantaleo, C. Rüegg M. Quadroni, K. Harshman and M-A Doucey Reduce expression of c-Cbl in effector vs central memory human CD4 T cells is responsible for lower threshold of activation (2008) Blood, 112(3):652-60. PubMed

Y. Monnier, P. Farmer, G. Bieler, N. Imaizumi, S. Andrejevic-Blant, T. Seenstag, Schutze, N., S.L. Goodman, R. Moeckli, R-O. Mirimanoff, M. Delorenzi, and C. Rüegg CYR61 and αVβ5 integrin cooperate to promote invasion and metastasis of tumors growing in pre-irradiated stroma (2008) Cancer Res, 68(18):7323-7331. PubMed

N. C. Brembilla, I. Cohen-Salmon, J.Weber, C. Rüegg, M. Quadroni, K. Harshman and M. A. Doucey. Profiling of signaling proteins and T cell receptor signaling complex assembly in human CD4 T lymphocytes using reverse phase protein arrays (2008) Proteomics, in press

G. Lorusso and C. Rüegg (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 130:1091-103 PubMed

Rüegg, C., Tissot, J.D., Farmer, P., and Mariotti, A. (2008) "Omics meets hypothesis-driven research- partnership for innovative discoveries in vascular biology." Thromb Haemost, 100:738-46. PubMed

Ronet C., Voigt H., Himmelrich H., Doucey M.-A., Breton M., Hauyon-Latorre Y., Tacchini-Cottier F., Bron C., Louis J. and Launois P. L. Major-specific B cells are necessary for Th2 cell development and susceptibility to infection with L. Major LV39. J. Immunol. 2008, 180 (7):4825-35   PubMed

Hartmann S., Doucey M.-A., Grob M., Rush J.S., Waechter J.W., Hofsteenge J. Partial purification and characterization of protein C-mannosyltransferase, a mammalian enzyme involved in C-glycosidic bond formation. J. Biol. Chem. 2008. Under submission.

Brunner J.-M., Plattet P., Rosso L., Doucey M.-A., Curie T., Wittek R., Vandelvelde M., ZurbriggenA.,  Harald Hirling and Desvergne B. Virulent morbillivirus induces ER stress and calreticulin cleavage. 2008. Under submission.



Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways.J Thromb Haemost. 2007 jan; 5:166-73 PubMed

G. Bieler, M. Hasmim, Y. Monnier, N. Imaizumi, M. Ameyar, J. Bamat, L. Ponsonnet, S. Chouaib, M. Grell, S. L. Goodman, F. Lejeune and C. Rüegg. (2007) Distinctive role of integrin-mediated adhesion in TNF-induced PKB and NF-kB activation and relevance to endothelial cell survival. Oncogene, 2007 Aug 23;26(39):5722-32. Epub 2007 Mar 19. PubMed

A Mariotti , A Perotti , C Sessa, and C Rüegg. N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs. 16:451-465. PubMed

N. Mutter and C. Rüegg. Anti-angiogenic therapies in cancer : achievements and open questions. Bull Cancer. 2007 Sep 1;94(9):753-62. PubMed

R. Stupp, and C. Rüegg (2007) Integrin inhibitors reaching the clinic J Clin Oncol. 2007 May 1;25(13):1637-8. PubMed

R. Meier, N. Gross Nicole, Mühlethaler-Mottet, M. Flahaut, C. Fusco Carlo, F. Louache, K. Auderset, K. Balmas Bourloud, C. Ruegg, G. Vassal, JM. Joseph. (2007) CXCR4 expression on Neuroblastoma Cells has differential effects on tumor growth and metastasis depending on their intrinsic malignant potential. PLoS One, Oct 10;2(10):e1016. PubMed



Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006 Mar 22;6:6. Review   PubMed

K. Zaman, R. Driscoll, P. Werffeli, J. Bauer, S. Leyvraz, F. Lejeune, R. Stupp, and C. Rüegg. (2005) Monitoring multiple angiogenesis-related molecules in the blood of cancer patients before and after treatment reveals differential patterns and behaviors and association between VEGF and MMP-9.Int. J. Cancer,2006 Feb 1;118(3):755-64   PubMed

V. Villard, O. Kalyuzhniy O. Riccio, S. Potekhin, T. N. Melnik, A.V. Kajava, C. Rüegg and G. Corradin (2005) Synthetic RGD-containing α-Helical Coiled Coil Peptides promote Integrin-Dependent Cell Adhesion.J. Peptide Sci., 2006 Mar;12 (3): 206-12   PubMed

Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.  Endothelium. 2006 Mar-Apr;13(2):113-35   PubMed

Ruegg C, Hasmim M, Lejeune FJ, Alghisi GC. Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim Biophys Acta. 2006 Apr;1765(2):155-77   PubMed

Lejeune FJ, Monnier Y, Ruegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res. 2006 Jun;16(3):263-5   PubMed

Ruegg C. Leukocytes,inflammation, and angiogenesis in cancer: fatal attractions. J Leukoc Biol. 2006 Oct;80 (4) :682-4.   PubMed

Lejeune FJ, Ruegg C. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.Bull Cancer. 2006 Aug 1; 93(8): E90-100   PubMed

Doucey M.-A., Bender F., Hess D., Hofsteenge J., Bron C. Caveolin-1 interacts with the chaperone complex TCP-1 and modulates its protein folding activity. Cell Mol. Life Sci. 2006 (7-8): 939-49   PubMed



Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):31-8.   PubMed

O. Zaric J, Ruegg C. Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J Biol Chem. 2005 Jan 14;280(2):1077-85. Epub 2004 Nov 3.   PubMed

A. Foletti, G-C. Alghisi, L. Ponsonnet and C. Rüegg. (2005) Isolated integrin β1 and β3 subunit cytoplasmic domains require membrane anchorage to recruit to adhesion complexes but cannot discriminate between β1-fibrillar adhesions and β3+-focal adhesions. Thromb. Haemost. 2005 Jul;94(1):155-66   PubMed

M. Hasmim, G. Vassalli, L. Ponsonnet, G. Vassalli, J. Bamat, C. Bieler, J. Paroz, D. Oguey, and C. Rüegg. (2005) Endothelial cell death induced by expression of isolated integrin β1 subunit cytoplasmic domain in vitro and in vivo is secondary to cell detachment Thromb. Haemost. 2005 Nov;94(5):1060-70   PubMed

Broillet A, Hantson J, Ruegg C, Messager T, Schneider M. (2005) Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. Acad radiol. 2005 May;12 suppl 1:S28-33   PubMed

C. Rüegg (2005) Protein and peptide drugs to suppress tumor angiogenesis. In Delivery of protein and peptide drugs in cancer, Edited by V. Torchilin, World Scientific/Imperial College Press

Legler D.F., Doucey M.-A., Chapatte L., Schneider P, Bender C.F.and  Bron C. Differential insertion of cell surface painted GPI-anchored GFPs into lipid rafts of T lymphocytes. FASEB J. 2005, 19(1):73-5   PubMed


Chemin des Boveresses 155 - CH-1066 Epalinges  - Switzerland  -  Tel. +41 21 692 58 42  -  Fax +41 21 652 69 33
Swiss University